Technology Changes, Passion Remains

In 1948 Mike Lyon’s father took him and his younger brother up in a rented plane. His experience “at eight or nine years old” along with his brother’s made them both grow up to become pilots. Lyon has been flying for 67 years. Because “every single time is an adventure.”

Mike Lyon has been coming to the EAA AirVenture Air Show in OshKosh, Wisconsin since 1980 or ’81. “There’s no place you can go where you can see all the new innovations and toys that you may or may not, can or can’t afford to put into an airplane.” He says it’s a real learning experience with all the different vendors and merchandise.

Even if you don’t own your own plane, you’re bound to enjoy the sight of planes flying in formation overhead and the displays of planes from all eras, from prop planes to jets, and personally-built crafts to giant transport planes.

If you do own your own plane, though, this is really the place to be. Lyon not only enjoys seeing what’s new in airplane technology, but seeing old friends as well. That makes it “a homecoming, fun, and educational experience all at once.” Indeed, the latest and greatest mixes well at the AEE AirVenture Air Show with the traditional and even the vintage because, as Lyon notes, while the technology constantly changes, the art of flying remains the same.

For the latest news, videos, and podcasts in the Transportation Industry, be sure to subscribe to our industry publication.
Follow us on social media for the latest updates in B2B!
Twitter – @TransportMKSL

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More